SPS
SPRO icon

Susquehanna Portfolio Strategies’s Spero Therapeutics SPRO Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39K Buy
+17,628
New +$46.1K ﹤0.01% 828

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Susquehanna Portfolio Strategies's SPRO Position: Q2 2026 in Review

Susquehanna Portfolio Strategies opened a new position in Spero Therapeutics (SPRO) in Q2 2026: 17,628 shares worth $39K. The stake represents ﹤0.01% of the portfolio and ranks #828 among its holdings.

60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Susquehanna Portfolio Strategies held 17,628 shares of Spero Therapeutics worth $39K as of Q2 2026.
  • Spero Therapeutics was a new Susquehanna Portfolio Strategies position in Q2 2026.
  • Spero Therapeutics made up ﹤0.01% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #828 holding.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.